Olaparib shows promise in multiple tumor types.

Cancer discovery ·第 3 卷 ·第 7 期 ·2014-03-21

摘要

A phase II study of the PARP inhibitor olaparib (AstraZeneca) for cancer patients with inherited BRCA1 and BRCA2 gene mutations confirmed earlier results showing clinical benefit for advanced breast and ovarian cancers, and demonstrated evidence of effectiveness against pancreatic and prostate cancers.

文献信息

期刊

Cancer discovery

期刊简称

Cancer Discov

ISSN

2159-8274

DOI

10.1158/2159-8290.CD-NB2013-082

发表日期

2014-03-21

收录日期

2013-07-12

更新日期

2014-12-31

语言

英语

国家/地区

United States

NLM ID

101561693

外部链接

PubMed 原文 DOI: 10.1158/2159-8290.CD-NB2013-082 查看期刊详情

分析服务

Olaparib shows promise in multiple tumor types.

联系地址

微信公众号